新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Biogen的多发性硬化症药物Tecfidera继续普及

Biogen的多发性硬化症药物Tecfidera继续普及

来源:生物谷 2013-08-04 21:50

2013年8月4日讯 /生物谷BIOON/ --多发性硬化症一直是困扰人类的一个严重健康问题。因而也是各大药企急于抢占的市场。Biogen公司的口服治疗多发性硬化症药物Tecfidera药物在上市仅一季度后销售额达到1亿9千2百万美元,几乎是市场预计的两倍之多。(生物谷Bioon.com)

详细英文报道:

The market for multiple sclerosis medications is growing ever more crowded, especially with the advent of oral MS drugs, which are grabbing market share. One such pill is Biogen Idec's ($BIIB) Tecfidera, whiched raked in $192 million in sales its first quarter on the market--more than twice what some analysts expected. But Tecfidera is not stopping there. An investor note from Leerink Swann says the drug showed a 4.3% week-over-week increase in new prescriptions for the week ended July 26. While analyst Dr. Marko Kozul cautions that early data "may not be the best of Tecfidera's launch and long-term potential," he also calls the drug's launch "very impressive" overall.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库